Atacana Group > Resources Center > Reports > Migraine Key Catalysts for 2023
Dark Mode

Migraine Key Catalysts for 2023

Migraine Key Catalysts for 2023
Atacana Group

According to the American Migraine Foundation, migraine affects 1 in 4 households in the US, and over 1 billion people worldwide live with migraine.

While there is no cure for migraine, pharmaceutical companies continue to innovate to provide treatment options for patients suffering from migraine.

It is an exciting time for migraine treatment.
Since 2018, ten new products have become available for migraine treatment. New therapies include new classes of drugs, such as calcitonin gene-related peptide (CGRP) monoclonal antibodies and CGRP-targeting gepants.
Download this report to learn more about the Migraine Market.

Download The Migraine Catalysts 2023 Report